Prove Accelerates Global Innovation with Expansion of Ireland R&D Hub April 2, 2026 $5M investment and expanded Dublin team accelerates product strategy and supports Prove’s growing global customer base
Scottish AI and Software Development Firm Zudu Appoints New CEO and Moves Edinburgh HQ April 2, 2026 - New CEO Paul Duffy says big question for business leaders is do their companies have the delivery capability to close the AI gap - Zudu forecasting £5m revenue in current year and £10m by 2028
SecurityTech on the Rise: G+D Reports Strong Order Intake and High Resilience in 2025 April 2, 2026 In fiscal year 2025, Giesecke+Devrient (G+D) reaffirmed its position as global leader in SecurityTech for mission-critical infrastructure. In a market where security is becoming essential for technological and societal stability, G+D demonstrates strong growth prospects. In 2025, G+D achieved a record order intake of €3.6 billion (+8%). Revenue increased to €3.2 billion (+1%), although exchange [...]
Capitolis UK Approved to Operate an Organized Trading Facility (OTF) by the FCA March 31, 2026 Approval unlocks more optimization opportunities and efficiencies for clients and network
ECCEUKCH: The First Year of Activities to Promote European Extra Virgin Olive Oil in the UK and Switzerland Comes to a Close March 31, 2026 The first year of ECCEUKCH – The Excellence of European Olive Growing in the UK and Switzerland, the three-year information and promotion programme dedicated to high-quality European extra virgin olive oil, co-financed by the European Union under Regulation (EU) No 1144/2014, has come to an end. Promoted by the Tuscan Association of Olive Growers OL.MA. [...]
Alfasigma Reports Solid Performance in 2025 Supported by Double-Digit Revenue Growth in key strategic brands in Immunology (+17%1), Gastroenterology (+15%), Vascular (+10%), and Consumer Healthcare expansion portfolio in international markets March 31, 2026 Revenues of €1.8 billion (-4% versus PY) driven by solid performance across key therapeutic areas and global markets, partially offset by Ocaliva® withdrawal impact. Adjusted EBITDA2 of €350 million (-18% versus PY) underpinned by streamlined operational efficiencies and operating model evolution. Like-for-like Revenues up 7%, and EBITDA up 20%, adjusted for voluntarily withdrawal of Ocaliva® from US market. Marketing application under EMA review for the use of Jyseleca® in a new indication of axial spondyloarthritis (axSpA), a chronic inflammatory arthritis, to address unmet patient needs, submitted following the reporting period. Following the reporting period, agreement with GSK plc for worldwide exclusive rights to develop, manufacture and commercialise linerixibat; subsequently granted FDA approval for the US market (March 2026).
AviadoBio Advances AVB-101 Gene Therapy Program and Initiates Fourth Dose-Escalation Cohort of Phase 1/2 ASPIRE-FTD Trial March 31, 2026 Early biomarker and safety data show encouraging signals with plans to present additional data in 2H 2026 AviadoBio secures strategic investment from The Alzheimer’s Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) through their Treat FTD Fund to support ASPIRE-FTD Trial AviadoBio regains full rights to AVB-101 gene therapy program
TITAN Group Published the 2025 Integrated Annual Report March 27, 2026 Milestone Growth, Bold Acquisitions and a Strategy Built for the Future
Arm Expands Compute Platform to Silicon Products in Historic Company First March 24, 2026 News Highlights Arm extends its platform breadth to include production silicon products for the first time, offering the broadest choice of compute across IP, Arm Compute Subsystems (CSS) and silicon Introducing the first Arm-designed data center CPU, the Arm AGI CPU, for agentic AI infrastructure, delivering more than 2x performance per rack compared with x86 platforms* Developed with lead partner Meta, with other customers and leading ODMs committed for production, the Arm AGI CPU is backed by strong support from the global ecosystem
Trian and General Catalyst Agree to Increase Merger Consideration to $52.00 Per Share in Cash for Janus Henderson Group plc and Have Made the Only Actionable Proposal March 24, 2026 Amended Merger Agreement Represents a $3.00 All-Cash Price Increase; 25% Premium to Unaffected Share Price; Parties Committed to Closing by Mid-2026 Special Committee Determines that Victory Capital’s Revised Unsolicited March 17, 2026 Proposal Is Not Actionable and Is Not in Best Interests of Janus Henderson and Its Shareholders Amended Merger Agreement’s All-Cash Transaction With Trian and General Catalyst Is Superior From an Expected Value and Certainty Perspective and Is the Only Actionable Proposal